Bluelinx Holdings Inc

BXC is in an early Stage 2 advance following a breakout from its May–June consolidation, highlighted by a Momentum Breakout that overcame prior resistance with strong volume. The medium-term bias remains bullish given acceptance above rising EMAs and continuation signals, but short-term conditions are overextended and overbought. Execution should be deferred into a pullback toward the 9/20 EMA cluster around the former breakout zone for higher-probability long entries.

• ↑Q1 2026 revenue reached $731 M (+3% YoY) led by DeStero specialty sales
• ↑Adjusted EBITDA rose 20% YoY to $23.5 M via cost controls and volume gains
• ↓Gross margin only 15.9%; price deflation cut into specialty and structural segments